首页 | 本学科首页   官方微博 | 高级检索  
     

雾化吸入布地奈德与复方异丙托溴铵治疗慢性阻塞性肺疾病的临床分析
引用本文:杨永华,秦春美. 雾化吸入布地奈德与复方异丙托溴铵治疗慢性阻塞性肺疾病的临床分析[J]. 中外医疗, 2016, 0(5): 13-15. DOI: 10.16662/j.cnki.1674-0742.2016.05.013
作者姓名:杨永华  秦春美
作者单位:江苏省海门市第五人民医院内科,江苏南通,226131
摘    要:
目的:研究在慢性阻塞性肺疾病的临床治疗中雾化吸入布地奈德与复方异丙托溴铵的治疗效果。方法整群选取2014年7月—2015年7月在该院接受治疗的慢性阻塞性肺疾病患者70人,将这些病患随机分成两组,治疗组与对照组,每组病患35人,为对照组中的病患提供常规治疗,治疗组中的病患在对照组的基础上雾化吸入布地奈德与复方异丙托溴铵,统计学方法对比分析两组患者的治疗效果。结果治疗7d后,治疗组中病患的治疗总有效率为94.3%,对照组中病患的治疗总有效率为74.3%,治疗组高于对照组,差异有统计学意义(P<0.05),进一步分析显示治疗组脉搏血氧饱和度较对照组明显改善,脉氧改善起效时间明显短于对照组[(4.7±1.2) h vs(8.5±2.1) h]、持续稳定时间明显长于对照组[(23.5±2.8) h vs (16.7±3.2) h],差异均具有统计学意义(P<0.05)。结论在临床治疗慢性阻塞性肺疾病时,雾化吸入布地奈德与复方异丙托溴铵治疗效果良好,可在临床治疗中推广使用。

关 键 词:慢性阻塞性肺疾病  布地奈德  复方异丙托溴铵  雾化泵吸入

Clinical Analysis of Atomized Inhalation of Budesonide and Compound Ipratropium Bromide in the Treatment of Chronic Obstructive Pulmonary Disease
Abstract:
Objective To study the effect of atomized inhalation of budesonide and compound ipratropium bromide in the treatment of chronic obstructive pulmonary disease (COPD). Methods 70 cases with COPD treated in our hospital from July 2014 to July 2015 were selected and randomly divided into two groups, the treatment group and the control group with 35 cases in each. Patients in the control group were given the conventional treatment, and those in the treatment group were given the conventional treatment combined with atomized inhalation of budesonide and compound ipratropium bromide. And the treatment effect of the two groups was analyzed and compared statistically. Results After seven days of treatment, the total effective rate was much higher in the treatment group than in the control group (94.3%vs 74.3%) with statistically sig-nificant difference, P<0.05. Further analysis showed that the SpO2 improved more significantly in the treatment group com-pared with the control group. The onset time of improved SpO2 was much earlier in the treatment group than that in the control group [(4.7±1.2) h vs (8.5±2.1) h] with statistically significant difference, P<0.05. The duration of improved SpO2 was much longer in the treatment group than that in the control group [(23.5±2.8) h vs (16.7±3.2) h] with statistically significant difference, P<0.05. Conclusion In the clinical treatment of COPD, atomized inhalation of budesonide and compound iprat-ropium bromide has good effect, which can be widely applied to the clinical treatment.
Keywords:Chronic obstructive pulmonary disease  Budesonide  Compound ipratropium bromide  Atomizing pump inhala-tion
本文献已被 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号